TCTR20180703001进行中（未招募）未知
Factors affecting tyrosine kinase inhibitors response in chronic myeloid leukemia patients
/A0 个研究点目标入组 100 人开始时间: 2018年7月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 0 N/A (No limit)（—）
- 性别
- All
入选标准
- •â€¢Thai patients with chronic myeloid leukemia received tyrosine kinase inhibitors for at least 6 months in Srinagarind Hospital.
- •â€¢The patients are at least 18 years of age.
- •â€¢The patients are willing to participate in the study and signed a consent form.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Assessment of sensitivity and therapeutic response to next-line therapy in Chronic Myeloid Leukaemia (CML)Chronic Myeloid Leukaemia (CML)Cancer - Leukaemia - Chronic leukaemiaACTRN12610000055000Australasian Leukaemia and Lymphoma Group (ALLG)1,000
进行中（未招募）
不适用
Impact des Inhibiteurs de Tyrosine Kinase sur la fertilité masculine. GLIFERTI - GLIFERTIEUCTR2007-004497-11-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
已完成
不适用
Safety and efficacy of tyrosine kinase inhibitors for the treatment of severe and progressive pulmonary hypertensiopulmonary hypertensionJPRN-UMIN000015696Hokkaido University Hospital, Internal medicine I5
已完成
不适用
The Effect of Tyrosine Kinase Inhibitor on Thyroid Function in Patients with Chronic Myeloid LeukemiaChronic Myeloid LeukemiaJPRN-UMIN000015824Keio University School of Medicine100
进行中（未招募）
不适用
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)MedDRA version: 14.1Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10034877Term: Philadelphia chromosome positiveSystem Organ Class: 10022891 - InvestigationsEUCTR2010-022946-25-Outside-EU/EEAChildren's Oncology Group195